NCT07002827View on ClinicalTrials.gov

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Decompensated Liver Cirrhosis
Interventions
DRUG

Darbepoetin

Darbepoetin will be given s/c at dose of 40 mcg once a week (total 4 doses) for 1 month

DRUG

G-CSF

G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30

DRUG

Lactulose

Standard Medical Tretament part

BIOLOGICAL

Albumin

Standard Medical Tretament part

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT07002827 - Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. | Biotech Hunter | Biotech Hunter